BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more
BORA PHARMACEUTICALS LTD (6472) - Total Liabilities
Latest total liabilities as of September 2025: NT$28.05 Billion TWD
Based on the latest financial reports, BORA PHARMACEUTICALS LTD (6472) has total liabilities worth NT$28.05 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BORA PHARMACEUTICALS LTD - Total Liabilities Trend (2019–2024)
This chart illustrates how BORA PHARMACEUTICALS LTD's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BORA PHARMACEUTICALS LTD Competitors by Total Liabilities
The table below lists competitors of BORA PHARMACEUTICALS LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Elgi Equipments Limited
NSE:ELGIEQUIP
|
India | ₹11.69 Billion |
|
Cibus Nordic Real Estate AB (publ)
ST:CIBUS
|
Sweden | Skr1.67 Billion |
|
Datang HuaYin Electric Power Co Ltd
SHG:600744
|
China | CN¥26.53 Billion |
|
MVV Energie AG
F:MVV1
|
Germany | €4.11 Billion |
|
IHS Holding Ltd
NYSE:IHS
|
USA | $4.65 Billion |
|
dentalcorp Holdings Ltd.
PINK:DNTCF
|
USA | $1.66 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down BORA PHARMACEUTICALS LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BORA PHARMACEUTICALS LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BORA PHARMACEUTICALS LTD (2019–2024)
The table below shows the annual total liabilities of BORA PHARMACEUTICALS LTD from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | NT$30.59 Billion | +130.22% |
| 2023-09-30 | NT$13.29 Billion | -24.60% |
| 2022-09-30 | NT$17.62 Billion | +317.57% |
| 2021-09-30 | NT$4.22 Billion | -7.04% |
| 2020-09-30 | NT$4.54 Billion | +162.56% |
| 2019-09-30 | NT$1.73 Billion | -- |